Publications by authors named "P Hendrickson"
Purpose: Optimal treatment of retroperitoneal sarcoma (RPS) remains undefined. Here, we report the feasibility of using high-dose boost radiation (3-4 Gy) to the central part of the tumor in patients with unresectable RPS.
Methods And Materials: Five patients with unresectable RPS were treated with radiation therapy using a central boost technique with intensity modulated radiation therapy.
Article Synopsis
- - The study examines the link between TP53 genetic variants and survival outcomes after stereotactic radiosurgery (SRS) in patients with brain metastases from non-small cell lung cancer (NSCLC).
- - Researchers analyzed data from 255 patients who received SRS between 2015 and 2020, finding that 56% had a pathogenic TP53 variant, but overall survival did not significantly differ based on TP53 status.
- - There was a suggestion that patients with a TP53 variant had better freedom from local progression compared to those without, indicating the need for further research in larger studies.
CIC-rearranged sarcomas comprise a group of exceptionally aggressive round-cell sarcomas. These tumors most commonly demonstrate CIC::DUX4 fusion and show similar histopathology to Ewing sarcomas, though lesions mimicking vascular neoplasms have recently been described. Here, we describe a case of a patient with CIC::DUX4 fusion sarcoma identified using RNA-based molecular testing who was initially diagnosed with an endothelial neoplasm.
View Article and Find Full Text PDFPurpose: Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare cancer, and large international cooperative efforts are needed to evaluate the significance of clinical risk factors and immunoarchitectural patterns (IAPs) for all stages of pediatric and adult patients with NLPHL.
Methods: Thirty-eight institutions participated in the Global nLPHL One Working Group retrospective study of NLPHL cases from 1992 to 2021. We measured progression-free survival (PFS), overall survival (OS), transformation rate, and lymphoma-specific death rate.